Ligand id: 667

Name: icatibant

No information available.
Summary of Clinical Use
Icatibant has been approved to treat hereditary angiodema (HAE). The drug is under investigation for other conditions susceptible to bradykinin amelioration eg ACE inhibitor-induced angiodema, knee ostoearthritis and use during cardiopulmonary bypass surgery. Click here to link to Clinicaltrials.gov's records for this drug.
Mechanism Of Action and Pharmacodynamic Effects
Icatibant is an antagonist of the bradykinin B2 receptor (BDKRB2). Activation of this receptor produces inflammatory symptoms such as swelling, redness, increased temperature and pain, by mediating increased blood vessel permeability and dilation and causing contraction of smooth muscle cells. Therefore antagonism of receptor activation negates these effects.
External links